ASLN Profile
ASLAN Pharmaceuticals Limited is a clinical-stage biopharmaceutical company specializing in immunology, dedicated to developing innovative treatments aimed at transforming patient outcomes. The company's clinical pipeline features a range of advanced therapies, including ASLAN004, a monoclonal antibody currently in development for atopic dermatitis and other immunological conditions. Another key candidate, ASLAN003, is a small-molecule inhibitor targeting dihydroorotate dehydrogenase, designed to address autoimmune disorders.
ASLAN Pharmaceuticals is actively engaged in strategic collaborations to enhance its research and development efforts. The company has established a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd., focusing on developing immuno-oncology therapies targeting the AhR pathway. This partnership reflects ASLAN's commitment to advancing next-generation treatments for cancer and other complex diseases.
The company also maintains strategic alliances with prominent industry players such as Almirall, Array BioPharma, and CSL Limited. These collaborations support ASLAN Pharmaceuticals' efforts to leverage external expertise and resources, facilitating the development and commercialization of its innovative therapeutic candidates.
Founded in 2010 and headquartered in Singapore, ASLAN Pharmaceuticals Limited is at the forefront of biopharmaceutical research, focusing on immunological and autoimmune diseases. The company's global approach and robust partnership network position it as a significant contributor to the advancement of targeted therapies and improved patient care.
|
